Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials
You may also be interested in...
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says